UCB Agrees To Pay $34M Over Epilepsy Drug Labeling

Law360, New York (June 9, 2011, 2:58 PM EDT) -- The U.S. subsidiary of Belgian pharmaceuticals manufacturer UCB SA pled guilty Thursday to the off-label promotion of its epilepsy drug Keppra, and agreed to pay more than $34 million to resolve criminal and civil liability.

Smyrna, Ga.-based UCB Inc. pled guilty to a misdemeanor in connection with the company’s misbranding of Keppra in violation of the Federal Food, Drug and Cosmetic Act.

The government said the guilty plea and a related civil settlement marked a victory as prosecutors team up with the U.S. Department of Health...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.